Skyhawk says its Huntington’s drug improved symptoms in extension to Phase 1/2 trial
Skyhawk's SKY-0515 shows a 1.59-point cUHDRS improvement at 15 months in Huntington's patients as its Phase 2/3 program advances.
Skyhawk Therapeutics
Private
Skyhawk Therapeutics is a clinical-stage biotechnology company developing small-molecule RNA splicing modulators using its proprietary SkySTAR platform, with programs in neurology, oncology, autoimmune, and fibrotic diseases.
Company Info
Sector:Small Molecule Pharma
Headquarters:Waltham, Massachusetts, United States
Founded:2016
Website:www.skyhawktx.com/
Funding Round:Series C and partnership milestones
Total Funding:>$2B in pharma partnership economics (incl. $2B+ Merck KGaA deal)
Funding & Investor Relations
Notable Investors
- Bain Capital Life Sciences
- Verition Fund Management
- Healthcare-focused institutional investors
Upcoming Milestones & Key Dates
2026-Q3
Clinical readout
SKY-0515 interim FALCON-HD data
2026-Q4
Regulatory
Additional IND filings
Clinical Development Pipeline
SKY-0515
Target: HTT RNA splicingSKY-1215
Target: RNA splicingBMS-partnered program
Target: RNA splicingRecent News
Leadership Team
Bill Haney
Chief Executive Officer
Aaron Deves
Chief Commercial Officer
Kyle Dow
Vice President, Corporate Development